Skip to main content
Oncotarget logoLink to Oncotarget
. 2020 Oct 13;11(41):3749–3750. doi: 10.18632/oncotarget.27755

Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor

Suyoun Chung 1, Kyoko Kijima 1, Aiko Kudo 1, Yoshiko Fujisawa 1, Yosuke Harada 1, Akiko Taira 1, Naofumi Takamatsu 1, Takashi Miyamoto 1, Yo Matsuo 1, Yusuke Nakamura 2
PMCID: PMC7566805  PMID: 33110482

This article has been corrected: During image assembly, incorrect data was mistakenly used in Figure 5A, resulting in a duplicate image of the bottom two panels. The corrected Figure 5A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Figure 5. Molecular changes in OTS167-treated tumor tissue.

Figure 5

Immunohistochemical analysis using xenograft tissue collected on day 4. (A) DEPDC1, (B) FOXM1, (C) p21, and (D) p53 were examined (original magnification: x 400). Box plots represent the percentage of positive cells stained with each antibody. Horizontal lines represent mean and error bars indicating the interquartile ranges of 30 ROIs per group. * p < 0.0001 by ANOVA and t t-test.

Original article: Oncotarget. 2016; 7:18171–18182. 18171-18182. https://doi.org/10.18632/oncotarget.7685


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES